We are conducting Phase 2 trials of  taletrectinib in ROS1 positive NSCLC patients both as first-line and second-line treatments in China. More information about the ongoing Phase 2 trials may be found at with NCT04395677.

Two Phase 1 trials, one in the US and the other in Japan, have been completed and are currently in extension phase with 7 patients remaining under treatment.

More information about the Phase 1 program may be found at with NCT02279433, and NCT0267591. These trials have been closed to new patient enrollment.

“Taletrectinib (AB106/DS6051b) demonstrated meaningful clinical activity in advanced ROS1+NSCLC patients who are ROS1 TKI-naive or crizotinib-refractory and a manageable safety profile.”


– Sai-Hong Ignatius Ou, M.D., Ph.D.

Contact Us

For questions about ongoing clinical trials, please contact